SGX listing underscores pharma growth in emerging markets

China Medical System Holdings (CMS) has completed a secondary listing on the Singapore Exchange (SGX), marking a significant step in its international growth plans.

To coincide with the listing, CMS hosted a pharma industry forum on globalisation and commercialisation in emerging markets, attended by industry experts, investors, and business leaders. Discussions focused on opportunities for drug innovation, overseas partnerships, and expanding patient access in high-growth regions.

CMS executives outlined the company’s strategy to broaden its international presence, strengthen collaboration across the pharma value chain, and enhance its competitiveness in the global healthcare market.

The SGX listing is expected to improve CMS’s visibility among international investors and support its long-term vision of becoming a global player in innovative pharmaceuticals.

More information online